Companies/Senti Biosciences, Inc.

Company profile

Senti Biosciences, Inc.

NASDAQ: SNTI · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001854270Reports USD

#1095 of 1,394 Healthcare companies by revenue

EA Score

27D

FH 21DQ 31GM 28SS 40

v0.1 · 65/100 weight · provisional

↑ market scale, Piotroski F · ↓ operating margin, net margin

Methodology →

Revenue TTM

$38.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$61.4M

Employees

Market cap

$28.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$22.0k$22.0k2025

Net income-$61.4M-$61.4M2025

Operating income-$68.8M-$68.8M2025

Total assets$51.2M$51.2M2025

Liabilities$45.6M$45.6M2025

Equity$5.6M$5.6M2025

Revenue trend

FY2022 – FY2025 · USD

$2.3M

FY22

$3.3M

FY22

$2.0M

FY23

FY24

$22.0k

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Reportable100%

By geography

Not disclosed.

The read

Senti Biosciences, Inc. booked $22.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -279263.6% net margin.

Peers · Healthcare

IGC Pharma, Inc.46D Cryo-Cell International, Inc.63C Vivos Inc.48D SCYNEXIS, Inc.61C

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B87A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B73B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOTimothy K. Lu

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: SNTI

Employees34

IPO date2021-05-26

Latest filings

8-K2026-05-26 8-K2026-05-14 10-Q2026-05-14 8-K2026-05-01 8-K2026-04-01 8-K2026-03-27 10-K2026-03-27 8-K2026-03-19

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.